Spherical Crystallization as Particle Engineering Technique to Improve Processability of Poor Flowing Furosemide
DOI:
https://doi.org/10.37285/ijpsn.2013.6.1.11Abstract
The pharmaceutical industry is focusing on developing simple and economical formulations to meet desired drug delivery challenges. Tablet continues to be the most popular dosage form. From the manufacturing point of view tablets can be produced at much higher rate than any other dosage forms. The formulation of tablet must be optimized to achieve desired goals. Poor flow of active pharmaceutical ingredient may raise issues like loss of tablet hardness and weight variation. This may restrict the formulator to use granulation techniques or higher levels of lubricants and glidants to impart the flow, which may adversely affect dissolution and compaction. Furosemide is a class IV drug from BCS classification and possesses poor flow properties. The main objective of study was to improve the flow properties of furosemide and thereby improve its solubility leading ultimately improvements in its bioavailability. We used two different techniques of spherical crystallization to improve the flow properties of furosemide. Our results reveal that the spherical crystallization by neutralization technique is better method than wet spherical crystallization to improve the flow properties of furosemide. Flow properties of excipients also affect the compression process. In conclusion, spherical crystallization technique could be used to enhance the flow properties of furosemide.
Downloads
Metrics
Keywords:
Spherical crystallization, wet spherical crystallization, neutralization technique, bridging liquid, flow properties, tableting
Downloads
Published
How to Cite
Issue
Section
References
Chow AHL and Leung MWM (1996). A study of the mechanisms of wet spherical agglomeration of pharmaceutical powders. Drug Dev Ind Pharm 22: 357-371.
Christensen, Svend, Age and Ger Offer (1971). Analytical profiles of drug substances. Academic Press, Harcourt Brace Jovanovich, Publishers 18: 153 – 193
Farbwerke Hoechst A.G.Fr (1968). Analytical profiles of drug substances. Academic Press, Harcourt Brace Jovanovich, Publishers 18: 153 – 193.
Gupta VR, Mutalik S, Patel M and Girish K (2007). Spherical crystals of celecoxib to improve solubility,dissolution rate and micromeritic properties. Acta Pharm. 57: 173–184.
Kawashima Y and Handa T (1986). Crystal modification of phenytoin with polyethylene glycol for improving mechanical strength, dissolution rate, bioavailability by a spherical crystallization technique. Chem Pharm Bulletin 34: 3376-3383.
Kawashima Y, Cui F, Takeuchi H, Niwa T, Hino T and Kiuchi K(1995). Parameters determining the agglomeration behavior and the micromeritic properties of spherically agglomerated crystals prepared by the spherical crystallization technique with miscible solvent systems. Int J Pharm 119: 139-147.
Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K (2002). Development of agglomerated crystals of Ascorbic acid by the spherical crystallization techniques. Powder Technol 130: 283– 289.
Kuriki S T and handa T (1987). Particle design of tolbutamide in presence of soluble particle and surfactant by the spherical crystallization technique: improvement of dissolution rate. J.Pharm Sci. 76: 471 – 474.
Lachman L and Lieberman H (1976). A. The Theory and Practice of Industrial Pharmacy, 2nd edition; Varghese publishing house, Mumbai 293-345.
Mahanty S and Sruti J (2010). Particle design of drugs by spherical crystallization techniques. Int J Pharm Sci Nanotech 3: 912-918.
Parida R (2010). Evaluation parameters for spherical agglomerates formed by spherical crystallization technique. International Journal of Pharma and BioSciences 1: 1-10.
Patil S V, Sahoo S K (2009). Spherical Crystallization: A method to improve tabletability. Research. J.Pharm. and Tech. 2: 234-237.
Sano A, Kuriki T, Y. Kawashima, H. Takeuchi and T. Hino, T. Niwa (1992). Particle design of tolbutamide in presence of soluble particle and surfactant by the spherical crystallization technique: improvement of dissolution and bioavailability of direct compressed tablets prepared using tolbutamide agglomerated crystals. Chem Pharm Bull 40: 3030–3035.
